| Tanell E Ogbeide, CFNP | |
|
18010 Sw Mcewan Rd, Lake Oswego, OR 97035-7868 | |
| (503) 525-7500 | |
| (503) 525-7515 |
| Full Name | Tanell E Ogbeide |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 22 Years |
| Location | 18010 Sw Mcewan Rd, Lake Oswego, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609108687 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Legacy Meridian Park Medical Center | Tualatin, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Legacy Meridian Park Hospital | 5092609842 | 89 |
News Archive
Researchers at Columbia University's Mailman School of Public Health analyzed the results of the Oregon Health Experiment, where eligible uninsured individuals were randomly assigned Medicaid or to stay with their current care. Considered controversial because the experiment found no measurable gains for physical health it did reveal benefits for mental health, financial wellbeing, and preventive screening.
The clinical threshold for undertaking elective surgery to remove part or all of the colon (colectomy) for people with inflammatory bowel disease (IBD) may be too high, warn researchers in a study published on bmj.com.
Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.
Newborn infant girls have better outcomes than their male counterparts due to an innate genetic advantage in responding to acute infections, according to new research from RCSI.
GenVec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic cancer.
› Verified 2 days ago
| Entity Name | Legacy Meridian Park Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184647620 PECOS PAC ID: 5092609842 Enrollment ID: O20040211001181 |
News Archive
Researchers at Columbia University's Mailman School of Public Health analyzed the results of the Oregon Health Experiment, where eligible uninsured individuals were randomly assigned Medicaid or to stay with their current care. Considered controversial because the experiment found no measurable gains for physical health it did reveal benefits for mental health, financial wellbeing, and preventive screening.
The clinical threshold for undertaking elective surgery to remove part or all of the colon (colectomy) for people with inflammatory bowel disease (IBD) may be too high, warn researchers in a study published on bmj.com.
Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.
Newborn infant girls have better outcomes than their male counterparts due to an innate genetic advantage in responding to acute infections, according to new research from RCSI.
GenVec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tanell E Ogbeide, CFNP Po Box 6689, Portland, OR 97228-6689 Ph: (503) 413-3900 | Tanell E Ogbeide, CFNP 18010 Sw Mcewan Rd, Lake Oswego, OR 97035-7868 Ph: (503) 525-7500 |
News Archive
Researchers at Columbia University's Mailman School of Public Health analyzed the results of the Oregon Health Experiment, where eligible uninsured individuals were randomly assigned Medicaid or to stay with their current care. Considered controversial because the experiment found no measurable gains for physical health it did reveal benefits for mental health, financial wellbeing, and preventive screening.
The clinical threshold for undertaking elective surgery to remove part or all of the colon (colectomy) for people with inflammatory bowel disease (IBD) may be too high, warn researchers in a study published on bmj.com.
Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.
Newborn infant girls have better outcomes than their male counterparts due to an innate genetic advantage in responding to acute infections, according to new research from RCSI.
GenVec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic cancer.
› Verified 2 days ago